Anti-Inflammatory and Angiogenic Effects of Stem Cell Secretome

Area of Science:

• Regenerative Medicine
• Biotechnology
• Cell Biology

Background:

• Mesenchymal stem cells (MSCs) secrete bioactive factors, including extracellular vesicles (EVs), which mediate therapeutic effects.
• The secretome of MSCs holds promise for treating degenerative diseases like osteoarthritis (OA).
• Characterizing MSC secretomes from clinically relevant, xeno-free sources is crucial for therapeutic development.

Purpose of the Study:

• To isolate and characterize the secretome and EVs from xeno-free human embryonic stem cell-derived MSCs (ES-MSCs) and infrapatellar fat pad-derived MSCs (IPFP-MSCs).
• To evaluate the biological activity of these secretomes and EVs on cell proliferation, microvascular formation, and cartilage degradation in an ex vivo OA model.

Main Methods:

• Concentrated conditioned media (CCM) and fractionated EVs were generated from ES-MSC and IPFP-MSC cultures.
• Vesicle characterization included nanoparticle tracking analysis, transmission electron microscopy, and flow cytometry.
• Biological activity was assessed using human umbilical vein endothelial cells (HUVECs), MSC proliferation assays, and an IL-1β-stimulated human OA cartilage explant model.

Main Results:

• Secretome preparations yielded approximately 50 billion EVs/mL with sizes between 50-200 nm, confirmed by TEM and surface marker analysis.
• CCM and EVs dose-dependently enhanced cell proliferation and stabilized endothelial network formation.
• ES-MSC CCM and EVs significantly reduced glycosaminoglycan release and suppressed catabolic gene expression (IL-1β, MMP-1, MMP-3) in OA cartilage explants.

Conclusions:

• Xeno-free ES-MSC and IPFP-MSC secretomes and their derived EVs are bioactive.
• These MSC-derived products demonstrate potential in promoting proliferation, angiogenesis, and mitigating cartilage degradation.
• MSC secretomes and EVs represent promising cell-free therapeutic strategies for osteoarthritis treatment.